Pediatric Endocrinology News

Children with mildly elevated thyroid-stimulating hormone levels at birth have normal thyroid function in mid-childhood and have neurocognitive abilities similar to their sibling controls, study data show.

Healio and Endocrine Today have compiled a list of the most read news from the virtual American Diabetes Association Scientific Sessions.

A substantial percentage of youths and young adults with diabetes in the U.S. are not achieving recommended glycemic outcomes despite newer therapies and greater availability of diabetes technology, according to SEARCH study data.

The FDA cleared an expanded pediatric indication for the t:slim X2 interoperable insulin pump, lowering its indicated age for use in children from age 14 years to age 6 years, according to a press release from Tandem.

Children’s Hospital of Philadelphia was once again named the No. 1 hospital in the country for pediatric diabetes and endocrinology by the U.S. News & World Report 2020-2021 Best Children’s Hospitals rankings.

Children with growth hormone deficiency assigned long-acting recombinant GH therapy experienced an increase in height velocity similar to children assigned daily injections, study data show.

In May, Healio readers were interested in sex hormones being investigated for treating COVID-19, greater COVID-19 complications for patients with diabetes and obesity, associations between thyroid dysfunction and working hours, and more.

A small study of young children with type 1 diabetes and their parents suggests that continuous glucose monitoring technology may improve a child’s sleep by minimizing wake periods during the night for blood glucose monitoring, whereas a parent’s sleep may be more disrupted by frequent nighttime blood glucose checks when using CGM, according to findings published in Diabetes Technology & Therapeutics.

Patients with elevated systolic BP, type 2 diabetes and obesity in early life had an accelerated progression of risk factors associated with early vascular aging, according to a study published in the Journal of the American Heart Association.

A leuprolide acetate suspension to be dosed every 6 months has been approved by the FDA for use in treating children aged at least 2 years with central precocious puberty, according to a press release from Tolmar Pharmaceuticals.